Tenosynovial giant cell tumor: a case report [PDF]
Journal of Medical Case Reports, 2023 Background This case reports the synchronous diagnosis of two rare unrelated diseases; leiomyosarcoma and tenosynovial giant cell tumor of the knee. It focuses on the challenges of diagnosing tenosynovial giant cell tumor, including cognitive biases in ...
Sonam Ansel +10 more
doaj +6 more sources
Clinical retrospective analysis with a predictive model for diffused-tenosynovial giant cell tumors of the temporomandibular joint [PDF]
BMC Cancer, 2023 Background This study aimed to find out the characteristics in relation to tumor recurrence in diffused-tenosynovial giant cell tumor of temporomandibular joint and to develop and validate the prognostic model for personalized prediction.
Ying Liu +7 more
doaj +3 more sources
Arthroplasty for tenosynovial giant cell tumors: 17 patients followed for 0.2 to 15 years [PDF]
Acta Orthopaedica, 2016 Background and purpose — Tenosynovial giant cell tumors (t-GCTs) can behave aggressively locally and affect joint function and quality of life. The role of arthroplasty in the treatment of t-GCT is uncertain.
Floortje G M Verspoor +4 more
doaj +4 more sources
Cerrahpaşa Medical Journal, 2023 Objective: Localized-type tenosynovial giant cell tumor is a rare, benign tumor that originates from synovial joints, tendon sheaths, and bursae. It has 2 forms: diffuse and localized.
Fatih Çınar +6 more
doaj +2 more sources
Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. [PDF]
Cancer, 2021 Background The objective of this study was to report on the long-term effects of pexidartinib on tenosynovial giant cell tumor (TGCT).Methods This was a pooled analysis encompassing 3 pexidartinib-treated TGCT cohorts: 1) a phase 1 extension study ...
Gelderblom H +15 more
europepmc +4 more sources
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. [PDF]
Oncologist, 2021 Altres ajuts: National Institutes of Health/National Cancer Institute (P30 CA008748); Daiichi Sankyo, Co., Ltd.Background: Pexidartinib is approved in the U.S. for tenosynovial giant cell tumors (TGCTs).
Lewis JH +14 more
europepmc +6 more sources
Tenosynovial giant cell tumors as accidental findings after episodes of distortion of the ankle: two case reports [PDF]
Journal of Medical Case Reports, 2009 Introduction Tenosynovial giant cell tumors are benign tumors of uncertain pathogenesis. They occur in the joints, tendons and synovial bursas. Due to a high recurrence rate of up to 50%, some authors call a giant cell tumor a semimalignant tumor.
Poll Ludger W +4 more
doaj +2 more sources
Unmasking Coincident Hodgkin Lymphoma and Giant Cell Tumor: Insights from [18F] FDG PET/CT [PDF]
Asia Oceania Journal of Nuclear Medicine and BiologyTenosynovial giant cell tumors represent a group of typically non-malignant tumors found within the joints and soft tissues. The occurrence of tenosynovial giant cell tumor alongside hematologic malignancies is an infrequent finding.
Akram Al-ibraheem +4 more
doaj +3 more sources
Tenosynovial giant cell tumor with extensive myxoid change: A rare variant of a common tumor
Human Pathology: Case Reports, 2018 Tenosynovial giant cell tumor is a common tumor of synovial origin that usually occurs between the ages of 30 and 50 years. It is classified into localized and diffuse types based on the presence of a capsule around the lesion.
Jerry C. Nagaputra, Kesavan Sittampalam
doaj +2 more sources
Tenosynovial Giant Cell Tumor of the thigh [PDF]
International Archives of Medicine, 2017 Tenosynovial giant cell tumors (TGCT) are a group of generally benign intra-articular and soft tissue tumors with common histological features. TGCT is also known as pigmented villonodular synovitis. There are localized and diffuse forms. Localized types include giant cell tumors of tendon sheath and localized pigmented villonodular synovitis, whereas ...
Khaled Rahal +5 more
openaire +2 more sources